BACKGROUND: Increased production of cell-free DNA (cf-DNA), a marker of inflammation, cell death and degeneration, has been observed in stroke and severe traumatic brain injury among other medical conditions. The purpose of the present study was to evaluate the significance of cf-DNA in patients with focal epilepsy. METHODS: cf-DNA was measured in 167 consecutive well-evaluated patients with focal epilepsy (147 with refractory epilepsy). Epilepsy was characterized based on the patient history, electroclinical findings, neuroimaging results and etiology. 250 healthy individuals served as control subjects. RESULTS: The majority of the patients (125/167; 74.8%) had increased concentrations of cf-DNA. The median concentration of cf-DNA was significantly higher in the patients (0.867 μg/ml) compared to the control group (0.759 μg/ml) (p<0.001). Symptomatic etiology was associated with increased concentrations of cf-DNA compared to probably symptomatic etiology (p=0.036). CONCLUSIONS: The study confirms that the release of cf-DNA is more active in symptomatic refractory focal epilepsy, whereas this process is less pronounced in patients with unknown cause of epilepsy.
BACKGROUND: Increased production of cell-free DNA (cf-DNA), a marker of inflammation, cell death and degeneration, has been observed in stroke and severe traumatic brain injury among other medical conditions. The purpose of the present study was to evaluate the significance of cf-DNA in patients with focal epilepsy. METHODS: cf-DNA was measured in 167 consecutive well-evaluated patients with focal epilepsy (147 with refractory epilepsy). Epilepsy was characterized based on the patient history, electroclinical findings, neuroimaging results and etiology. 250 healthy individuals served as control subjects. RESULTS: The majority of the patients (125/167; 74.8%) had increased concentrations of cf-DNA. The median concentration of cf-DNA was significantly higher in the patients (0.867 μg/ml) compared to the control group (0.759 μg/ml) (p<0.001). Symptomatic etiology was associated with increased concentrations of cf-DNA compared to probably symptomatic etiology (p=0.036). CONCLUSIONS: The study confirms that the release of cf-DNA is more active in symptomatic refractory focal epilepsy, whereas this process is less pronounced in patients with unknown cause of epilepsy.
Authors: Sonia Mayo; Irene Gómez-Manjón; Francisco Javier Fernández-Martínez; Ana Camacho; Francisco Martínez; Julián Benito-León Journal: Int J Mol Sci Date: 2022-04-28 Impact factor: 6.208
Authors: Donal J Cox; Robert H Field; David G Williams; Marcin Baran; Andrew G Bowie; Colm Cunningham; Aisling Dunne Journal: Glia Date: 2015-01-27 Impact factor: 7.452
Authors: Kathryn McGuckin Wuertz; Piper M Treuting; Emily A Hemann; Katharina Esser-Nobis; Annelise G Snyder; Jessica B Graham; Brian P Daniels; Courtney Wilkins; Jessica M Snyder; Kathleen M Voss; Andrew Oberst; Jennifer Lund; Michael Gale Journal: PLoS Pathog Date: 2019-08-15 Impact factor: 6.823
Authors: Jordan H Whitlock; Tabea M Soelter; Avery S Williams; Andrew A Hardigan; Brittany N Lasseigne Journal: Hum Cell Date: 2021-10-25 Impact factor: 4.174
Authors: Elizaveta S Ershova; Galina V Shmarina; Lev N Porokhovnik; Natalia V Zakharova; George P Kostyuk; Pavel E Umriukhin; Sergey I Kutsev; Vasilina A Sergeeva; Natalia N Veiko; Svetlana V Kostyuk Journal: Genes (Basel) Date: 2022-03-20 Impact factor: 4.096